Approval of inhaled nitric oxide by the US Food and Drug Administration for hypoxic respiratory failure of the term and near-term newborn provides an important new therapy for this serious condition. This statement addresses the conditions under which inhaled nitric oxide should be administered to the neonate with hypoxic respiratory failure.

Subjects:
For Your Benefit
Topics:
hypoxia, nitric oxide, respiratory insufficiency, extracorporeal membrane oxygenation
Copyright © 2000 American Academy of Pediatrics
2000
You do not currently have access to this content.